Abstract: Objective The purpose of this study was to evaluate the efficacy and safety of sofosbuvir-velpatasvir regimen in the treatment of patients with chronic hepatitis C (CHC). Methods 108 patients with CHC were encountered in our hospital between January 2019 and December 2024, and were randomly assigned to receive coblopasvir in 54 cases in control, or sofosbuvir-velpatasvir in another 54 cases in observation for three months. Serum PC-III, LN, Col-IV and HA levels were measured by radioimmunoassay, and serum monocyte chemoattractant protein-4 (MCP-4), cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), macrophage inflammatory protein-3α (MIP-3α) and tumor necrosis factor alpha-induced protein 8-like 2 (TIPE2) levels were assayed by commercially available kits. Results Rapid virological response, end-treatment virological response and sustained virological response rates in the observation were 72.2%, 100.0% and 98.2%, all much higher than 44.4%, 64.8% and 64.8%(P＜0.05) in the control; after treatment, serum PC-Ⅲ, Col-Ⅳ and HA levels were (80.7±14.2)μg/L, (64.5±26.5)μg/L and (56.1±22.9)mg/L, all much lower than [(107.4±11.8)μg/L, (87.5±16.3)μg/L and (89.7±14.7)mg/L, respectively, P<0.05]in the control; serum MCP-4, MIP-3α, CTLA-4 and IL-12 levels were (93.1±20.3)pg/mL, (3113.2±83.4)pg/mL, (1.0±0.4)ng/mL and (24.6±7.3)pg/mL, all significantly lower than [(125.9±23.4)pg/mL, (3945.8±96.6)pg/mL, (1.6±0.6)ng/mL and (41.4±11.6)pg/mL, respectively, P<0.05], while serum TIPE2 level was (0.9±0.2)μg/L, significantly higher than [(0.6±0.2)μg/L, P＜0.05]in the control group. Conclusion Sofosbuvir/velpatasvir regimen demonstrates a definite clinical efficacy in the treatment of patients with CHC, which might improve immune-inflammatory status.

Key words: Hepatitis C, Sofosbuvir/velpatasvir, Coblopasvir, Cytotoxic T-lymphocyte-associated antigen 4, Therapy